Abstract
One of the most recently described clinical associations with SARS-CoV-2 infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound COVID-19 have been associated with cessation of treatment with the combined oral antiviral agent nirmatrelvir/ritonavir (Paxlovid). On 24 May 2022, the US Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory update for patients, healthcare providers, and public health departments on COVID-19 rebound or recurrence of COVID-19. However, population data from the US showed no significant differences in the risk of developing rebound COVID-19 between patients treated with Paxlovid and Molnupiravir. The mechanisms of rebound COVID-19 remain unclear but may involve the development of resistance to the antiviral drug, impaired immunity to the virus, or insufficient drug dosing. A further explanation may be the persistence of a high viral load of SARS-CoV-2 in individuals who are no longer symptomatic. This Editorial aims to provide an update on what is known about rebound COVID-19 and the current public health implications.
【초록키워드】 COVID-19, Treatment, public health, SARS-CoV-2, Immunity, Antiviral, SARS-COV-2 infection, risk, prevention, Antiviral treatment, virus, Case report, antiviral drug, CDC, Viral load, persistence, symptomatic, Control, network, patients, mechanism, association, Paxlovid, Implications, no significant difference, individual, center, healthcare providers, MOST, editorial, FIVE, described, eight, occur, patients treated, 【제목키워드】 COVID-19, SARS-CoV-2, Paxlovid, rebound,